Market Research Logo

Lupus Nephritis - Pipeline Review, H2 2015

Lupus Nephritis - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Lupus Nephritis - Pipeline Review, H2 2015’, provides an overview of the Lupus Nephritis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Lupus Nephritis Overview
Therapeutics Development
Pipeline Products for Lupus Nephritis - Overview
Pipeline Products for Lupus Nephritis - Comparative Analysis
Lupus Nephritis - Therapeutics under Development by Companies
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes
Lupus Nephritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lupus Nephritis - Products under Development by Companies
Lupus Nephritis - Products under Investigation by Universities/Institutes
Lupus Nephritis - Companies Involved in Therapeutics Development
AbbVie Inc.
Asahi Kasei Pharma Corp.
Azano Pharmaceuticals Inc.
Biogen, Inc.
Bristol-Myers Squibb Company
Deltanoid Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
FibroStatin SL
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Invion Limited
Millennium Pharmaceuticals, Inc.
Ocata Therapeutics, Inc.
Zyrnat Biotherapeutics SL
Lupus Nephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
abatacept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BIIB-023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMS-986147 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FSMAB-26 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HL-161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INV-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mizoribine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Lupus Nephritis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
obinutuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
P-Dex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5461111 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
venetoclax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
voclosporin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Y-175L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZY-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lupus Nephritis - Recent Pipeline Updates
Lupus Nephritis - Dormant Projects
Lupus Nephritis - Discontinued Products
Lupus Nephritis - Product Development Milestones
Featured News & Press Releases
Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis
Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers
Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers
Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis
May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH
Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lupus Nephritis, H2 2015
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Investigation by Universities/Institutes, H2 2015
Lupus Nephritis - Pipeline by AbbVie Inc., H2 2015
Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2015
Lupus Nephritis - Pipeline by Biogen, Inc., H2 2015
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2015
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2015
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Lupus Nephritis - Pipeline by FibroStatin SL, H2 2015
Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2015
Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Lupus Nephritis - Pipeline by Invion Limited, H2 2015
Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Lupus Nephritis - Pipeline by Ocata Therapeutics, Inc., H2 2015
Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H2 2015
Lupus Nephritis - Dormant Projects, H2 2015
Lupus Nephritis - Dormant Projects (Contd...1), H2 2015
Lupus Nephritis - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Lupus Nephritis, H2 2015
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report